Search

Your search keyword '"Marijnen, Corrie A. M."' showing total 284 results
Start Over Author "Marijnen, Corrie A. M."
284 results on '"Marijnen, Corrie A. M."'

1. Results of a diagnostic imaging audit in a randomised clinical trial in rectal cancer highlight the importance of careful planning and quality control

Author

Prata, Ilaria, Eriksson, Martina, Krdzalic, Jasenko, Kranenbarg, Elma Meershoek-Klein, Roodvoets, Annet G. H., Beets-Tan, Regina, van de Velde, Cornelis J. H., van Etten, Boudewijn, Hospers, Geke A. P., Glimelius, Bengt, Nilsson, Per J., Marijnen, Corrie A. M., Peeters, Koen C. M. J., and Blomqvist, Lennart K.

Published
2023
Full Text
View/download PDF

2. Evaluation of National Surgical Practice for Lateral Lymph Nodes in Rectal Cancer in an Untrained Setting

Author

Sluckin, Tania C., Hazen, Sanne-Marije J. A., Horsthuis, Karin, Beets-Tan, Regina G. H., Aalbers, Arend G. J., Beets, Geerard L., Boerma, Evert-Jan G., Borstlap, Jaap, van Breest Smallenburg, Vivian, Burger, Jacobus W. A., Crolla, Rogier M. P. H., Daniëls-Gooszen, Alette W., Davids, Paul H. P., Dunker, Michalda S., Fabry, Hans F. J., Furnée, Edgar J. B., van Gils, Renza A. H., de Haas, Robbert J., Hoogendoorn, Stefan, van Koeverden, Sebastiaan, de Korte, Fleur I., Oosterling, Steven J., Peeters, Koen C. M. J., Posma, Lisanne A. E., Pultrum, Bareld B., Rothbarth, Joost, Rutten, Harm J. T., Schasfoort, Renske A., Schreurs, Wilhelmina H., Simons, Petra C. G., Smits, Anke B., Talsma, Aaldert K., The, G. Y. Mireille, van Tilborg, Fiek, Tuynman, Jurriaan B., Vanhooymissen, Inge J. S., van de Ven, Anthony W. H., Verdaasdonk, Emiel G. G., Vermaas, Maarten, Vliegen, Roy F. A., Vogelaar, F. Jeroen, de Vries, Marianne, Vroemen, Joy C., van Vugt, Sebastiaan T., Westerterp, Marinke, van Westreenen, Henderik L., de Wilt, Johannes H. W., van der Zaag, Edwin S., Zimmerman, David D. E., Marijnen, Corrie A. M., Tanis, Pieter J., and Kusters, Miranda

Published
2023
Full Text
View/download PDF

3. ASO Visual Abstract: Evaluation of National Surgical Practice for Lateral Lymph Nodes in Rectal Cancer in an Untrained Setting

Author

Sluckin, Tania C., Hazen, Sanne-Marije J. A., Horsthuis, Karin, Beets-Tan, Regina G. H., Aalbers, Arend G. J., Beets, Geerard L., Boerma, Evert-Jan G., Borstlap, Jaap, van Breest Smallenburg, Vivian, Burger, Jacobus W. A., Crolla, Rogier M. P. H., Daniëls-Gooszen, Alette W., Davids, Paul H. P., Dunker, Michalda S., Fabry, Hans F. J., Furnée, Edgar J. B., van Gils, Renza A. H., de Haas, Robbert J., Hoogendoorn, Stefan, van Koeverden, Sebastiaan, de Korte, Fleur I., Oosterling, Steven J., Peeters, Koen C. M. J., Posma, Lisanne A. E., Pultrum, Bareld B., Rothbarth, Joost, Rutten, Harm J. T., Schasfoort, Renske A., Schreurs, Wilhelmina H., Simons, Petra C. G., Smits, Anke B., Talsma, Aaldert K., The, G. Y. Mireille, van Tilborg, Fiek, Tuynman, Jurriaan B., Vanhooymissen, Inge J., van de Ven, Anthony W. H., Verdaasdonk, Emiel G. G., Vermaas, Maarten, Vliegen, Roy F. A., Vogelaar, F. Jeroen, de Vries, Marianne, Vroemen, Joy C., van Vugt, Sebastiaan T., Westerterp, Marinke, van Westreenen, Henderik L., de Wilt, Johannes H. W., van der Zaag, Edwin S., Zimmerman, David D. E., Marijnen, Corrie A. M., Tanis, Pieter J., and Kusters, Miranda

Published
2023
Full Text
View/download PDF

4. Current controversies in TNM for the radiological staging of rectal cancer and how to deal with them: results of a global online survey and multidisciplinary expert consensus

Author

Lambregts, Doenja M. J., Bogveradze, Nino, Blomqvist, Lennart K., Fokas, Emmanouil, Garcia-Aguilar, Julio, Glimelius, Bengt, Gollub, Marc J., Konishi, Tsuyoshi, Marijnen, Corrie A. M., Nagtegaal, Iris D., Nilsson, Per J., Perez, Rodrigo O., Snaebjornsson, Petur, Taylor, Stuart A., Tolan, Damian J. M., Valentini, Vincenzo, West, Nicholas P., Wolthuis, Albert, Lahaye, Max J., Maas, Monique, Beets, Geerard L., and Beets-Tan, Regina G.H.

Published
2022
Full Text
View/download PDF

5. Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance–Guided Radiotherapy

Author

Westerhoff, Jasmijn M., primary, Daamen, Lois A., additional, Christodouleas, John P., additional, Blezer, Erwin L. A., additional, Choudhury, Ananya, additional, Westley, Rosalyne L., additional, Erickson, Beth A., additional, Fuller, Clifton D., additional, Hafeez, Shaista, additional, van der Heide, Uulke A., additional, Intven, Martijn P. W., additional, Kirby, Anna M., additional, Lalondrelle, Susan, additional, Minsky, Bruce D., additional, Mook, Stella, additional, Nowee, Marlies E., additional, Marijnen, Corrie A. M., additional, Orrling, Kristina M., additional, Sahgal, Arjun, additional, Schultz, Christopher J., additional, Faivre-Finn, Corinne, additional, Tersteeg, Robbert J. H. A., additional, Tree, Alison C., additional, Tseng, Chia-Lin, additional, Schytte, Tine, additional, Silk, Dustin M., additional, Eggert, Dave, additional, Luzzara, Marco, additional, van der Voort van Zyp, Jochem R. N., additional, Verkooijen, Helena M., additional, and Hall, William A., additional

Published
2024
Full Text
View/download PDF

8. Impact of the new rectal cancer definition on multimodality treatment and interhospital variability: Results from a nationwide cross‐sectional study.

Author

Hazen, Sanne‐Marije J. A., Sluckin, Tania C., Horsthuis, Karin, Lambregts, Doenja M. J., Beets‐Tan, Regina G. H., Hompes, Roel, Buffart, Tineke E., Marijnen, Corrie A. M., Tanis, Pieter J., Kusters, Miranda, Aalbers, Arend G. J., van Aalten, Susanna M., Amelung, Femke J., Ankersmit, Marjolein, Antonisse, Imogeen E., Ashruf, Jesse F., Aukema, Tjeerd S., Avenarius, Henk, Bahadoer, Renu R., and Bakers, Frans C. H.

Subjects
RECTAL cancer, COLON cancer, DELPHI method, CROSS-sectional method, PROGNOSIS
Abstract

Aim: This study aimed to determine the consequences of the new definition of rectal cancer for decision‐making in multidisciplinary team meetings (MDT). The new definition of rectal cancer, the lower border of the tumour is located below the sigmoid take‐off (STO), was implemented in the Dutch guideline in 2019 after an international Delphi consensus meeting to reduce interhospital variations. Method: All patients with rectal cancer according to the local MDT, who underwent resection in 2016 in the Netherlands were eligible for this nationwide collaborative cross‐sectional study. MRI‐images were rereviewed, and the tumours were classified as above or on/below the STO. Results: This study registered 3107 of the eligible 3178 patients (98%), of which 2784 patients had an evaluable MRI. In 314 patients, the tumour was located above the STO (11%), with interhospital variation between 0% and 36%. Based on TN‐stage, 175 reclassified patients with colon cancer (6%) would have received different treatment (e.g., omitting neoadjuvant radiotherapy, candidate for adjuvant chemotherapy). Tumour location above the STO was independently associated with lower risk of 4‐year locoregional recurrence (HR 0.529; p = 0.030) and higher 4‐year overall survival (HR 0.732; p = 0.037) compared to location under the STO. Conclusion: By using the STO, 11% of the prior MDT‐based diagnosis of rectal cancer were redefined as sigmoid cancer, with potential implications for multimodality treatment and prognostic value. Given the substantial interhospital variation in proportion of redefined cancers, the use of the STO will contribute to standardisation and comparability of outcomes in both daily practice and trial settings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Lymph node regression after neoadjuvant chemoradiotherapy in rectal cancer

Author

Ozturk, Sonay K, primary, Martinez, Cristina G, additional, Mens, David, additional, Verhoef, Cornelis, additional, Tosetto, Miriam, additional, Sheahan, Kieran, additional, de Wilt, Johannes H W, additional, Hospers, Geke A P, additional, van de Velde, Cornelis J H, additional, Marijnen, Corrie A M, additional, van der Post, Rachel S, additional, and Nagtegaal, Iris D, additional

Published
2024
Full Text
View/download PDF

11. Oncological Outcomes after a Pathological Complete Response Following Total Neoadjuvant Therapy or Chemoradiotherapy for High-Risk Locally Advanced Rectal Cancer in the RAPIDO Trial

Author

Zwart, Wouter Herman, primary, Temmink, Sofieke J.D., additional, Hospers, Geke A.P., additional, Marijnen, Corrie A. M., additional, Putter, H., additional, Nagtegaal, Iris D., additional, Blomqvist, Lennart, additional, Meershoek-Klein Kranenbarg, Elma, additional, Roodvoets, Annet, additional, Martling, Anna, additional, van de Velde, Cornelis, additional, Glimelius, Bengt, additional, Peeters, Koen, additional, van Etten, Boudewijn, additional, and Nilsson, Per, additional

Published
2024
Full Text
View/download PDF

14. Towards Response ADAptive Radiotherapy for organ preservation for intermediate-risk rectal cancer (preRADAR): protocol of a phase I dose-escalation trial

Author

Verweij, Maaike E, primary, Tanaka, Max D, additional, Kensen, Chavelli M, additional, van der Heide, Uulke A, additional, Marijnen, Corrie A M, additional, Janssen, Tomas, additional, Vijlbrief, Tineke, additional, van Grevenstein, Wilhelmina M U, additional, Moons, Leon M G, additional, Koopman, Miriam, additional, Lacle, Miangela M, additional, Braat, Manon N G J A, additional, Chalabi, Myriam, additional, Maas, Monique, additional, Huibregtse, Inge L, additional, Snaebjornsson, Petur, additional, Grotenhuis, Brechtje A, additional, Fijneman, Remond, additional, Consten, Esther, additional, Pronk, Apollo, additional, Smits, Anke B, additional, Heikens, Joost T, additional, Eijkelenkamp, Hidde, additional, Elias, Sjoerd G, additional, Verkooijen, Helena M, additional, Schoenmakers, Maartje M C, additional, Meijer, Gert J, additional, Intven, Martijn, additional, and Peters, Femke P, additional

Published
2023
Full Text
View/download PDF

16. Abandonment of Routine Radiotherapy for Nonlocally Advanced Rectal Cancer and Oncological Outcomes

Author

Hazen, Sanne-Marije J. A., Sluckin, Tania C., Intven, Martijn P. W., Beets, Geerard L., Beets-Tan, Regina G. H., Borstlap, Wernard A. A., Buffart, Tineke E., Buijsen, Jeroen, Burger, Jacobus W. A., van Dieren, Susan, Furnée, Edgar J. B., Geijsen, E. Debby, Hompes, Roel, Horsthuis, Karin, Leijtens, Jeroen W. A., Maas, Monique, Melenhorst, Jarno, Nederend, Joost, Peeters, Koen C. M. J., Rozema, Tom, Tuynman, Jurriaan B., Verhoef, Cornelis, de Vries, Marianne, van Westreenen, Henderik L., de Wilt, Johannes H.W., Zimmerman, David D. E., Marijnen, Corrie A. M., Tanis, Pieter J., and Kusters, Miranda

Abstract

IMPORTANCE: Neoadjuvant short-course radiotherapy was routinely applied for nonlocally advanced rectal cancer (cT1-3N0-1M0 with >1 mm distance to the mesorectal fascia) in the Netherlands following the Dutch total mesorectal excision trial. This policy has shifted toward selective application after guideline revision in 2014. OBJECTIVE: To determine the association of decreased use of neoadjuvant radiotherapy with cancer-related outcomes and overall survival at a national level. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, population-based, nationwide cross-sectional cohort study analyzed Dutch patients with rectal cancer who were treated in 2011 with a 4-year follow-up. A similar study was performed in 2021, analyzing all patients that were surgically treated in 2016. From these cohorts, all patients with cT1-3N0-1M0 rectal cancer and radiologically unthreatened mesorectal fascia were included in the current study. The data of the 2011 cohort were collected between May and October 2015, and the data of the 2016 cohort were collected between October 2020 and November 2021. The data were analyzed between May and October 2022. MAIN OUTCOMES AND MEASURES: The main outcomes were 4-year local recurrence and overall survival rates. RESULTS: Among the 2011 and 2016 cohorts, 1199 (mean [SD] age, 68 [11] years; 430 women [36%]) of 2095 patients (57.2%) and 1576 (mean [SD] age, 68 [10] years; 547 women [35%]) of 3057 patients (51.6%) had cT1-3N0-1M0 rectal cancer and were included, with proportions of neoadjuvant radiotherapy of 87% (2011) and 37% (2016). Four-year local recurrence rates were 5.8% and 5.5%, respectively (P = .99). Compared with the 2011 cohort, 4-year overall survival was significantly higher in the 2016 cohort (79.6% vs 86.4%; P < .001), with lower non–cancer-related mortality (13.8% vs 6.3%; P < .001). CONCLUSIONS AND RELEVANCE: The results of this cross-sectional study suggest that an absolute 50% reduction in radiotherapy use for nonlocally advanced rectal cancer did not compromise cancer-related outcomes at a national level. Optimizing clinical staging and surgery following the Dutch total mesorectal excision trial has potentially enabled safe deintensification of treatment.

Published
2024
Full Text
View/download PDF

17. Radiotherapy quality assurance for mesorectum treatment planning within the multi-center phase II STAR-TReC trial: Dutch results

Author

van den Ende, Roy P. J., Peters, Femke P., Harderwijk, Ernst, Rütten, Heidi, Bouwmans, Liza, Berbee, Maaike, Canters, Richard A. M., Stoian, Georgiana, Compagner, Kim, Rozema, Tom, de Smet, Mariska, Intven, Martijn P. W., Tijssen, Rob H. N., Theuws, Jacqueline, van Haaren, Paul, van Triest, Baukelien, Eekhout, Dave, Marijnen, Corrie A. M., van der Heide, Uulke A., and Kerkhof, Ellen M.

Published
2020
Full Text
View/download PDF

18. Mapping of sentinel lymph node drainage using SPECT/CT to tailor elective nodal irradiation in head and neck cancer patients (SUSPECT-2): a single-center prospective trial

Author

de Veij Mestdagh, Pieter D., Schreuder, Willem H., Vogel, Wouter V., Donswijk, Maarten L., van Werkhoven, Eric, van der Wal, Jacqueline E., Dirven, Richard, Karakullukcu, Baris, Sonke, Jan-Jakob, van den Brekel, Michiel W. M., Marijnen, Corrie A. M., and Al-Mamgani, Abrahim

Published
2019
Full Text
View/download PDF

19. Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery.

Author

Dijkstra, Esmée A., Nilsson, Per J., Hospers, Geke A. P., Bahadoer, Renu R., Kranenbarg, Elma Meershoek-Klein, Roodvoets, Annet G. H., Putter, Hein, Berglund, Åke, Cervantes, Andrés, Crolla, Rogier M. P. H., Hendriks, Mathijs P., Capdevila, Jaume, Edhemovic, Ibrahim, Marijnen, Corrie A. M., de Velde, Cornelis J. H. van, Glimelius, Bengt, and van Etten, Boudewijn

Abstract

Objective: To analyze risk and patterns of locoregional failure (LRF) in patients of the RAPIDO trial at 5 years. Background: Multimodality treatment improves local control in rectal cancer. Total neoadjuvant treatment (TNT) aims to improve systemic control while local control is maintained. At 3 years, LRF rate was comparable between TNT and chemoradiotherapy in the RAPIDO trial. Methods: A total of 920 patients were randomized between an experimental (EXP, short-course radiotherapy, chemotherapy, and surgery) and a standard-care group (STD, chemoradiotherapy, surgery, and optional postoperative chemotherapy). LRFs, including early LRF (no resection except for organ preservation/R2 resection) and locoregional recurrence (LRR) after an R0/R1 resection, were analyzed. Results: Totally, 460 EXP and 446 STD patients were eligible. At 5.6 years (median follow-up), LRF was detected in 54/460 (12%) and 36/446 (8%) patients in the EXP and STD groups, respectively (P=0.07), in which EXP patients were more often treated with 3-dimensional-conformed radiotherapy (P=0.029). In the EXP group, LRR was detected more often [44/431 (10%) vs. 26/428 (6%); P=0.027], with more often a breached mesorectum (9/44 (21%) vs. 1/26 (4); P=0.048). The EXP treatment, enlarged lateral lymph nodes, positive circumferential resection margin, tumor deposits, and node positivity at pathology were the significant predictors for developing LRR. Location of the LRRs was similar between groups. Overall survival after LRF was comparable [hazard ratio: 0.76 (95% CI, 0.46--1.26); P=0.29]. Conclusions: The EXP treatment was associated with an increased risk of LRR, whereas the reduction in disease-related treatment failure and distant metastases remained after 5 years. Further refinement of the TNT in rectal cancer is mandated. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. Features on Endoscopy and MRI after Treatment with Contact X-ray Brachytherapy for Rectal Cancer: Explorative Results

Author

Custers, Petra A., primary, Maas, Monique, additional, Lambregts, Doenja M. J., additional, Beets-Tan, Regina G. H., additional, Beets, Geerard L., additional, Peters, Femke P., additional, Marijnen, Corrie A. M., additional, van Leerdam, Monique E., additional, Huibregtse, Inge L., additional, and van Triest, Baukelien, additional

Published
2022
Full Text
View/download PDF

27. The immune microenvironment landscape shows treatment-specific differences in rectal cancer patients

Author

Martinez, Cristina Graham, Barella, Yari, Kus Öztürk, S., Ansems, M., Gorris, M.A.J., Vliet, S. van, Marijnen, Corrie A. M., and Nagtegaal, I.D.

Subjects
All institutes and research themes of the Radboud University Medical Center, Chemotherapy, Adjuvant, Rectal Neoplasms, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], Immunology, Tumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14], Tumor Microenvironment, Humans, Immunology and Allergy, Forkhead Transcription Factors, Chemoradiotherapy, Adjuvant, Neoadjuvant Therapy
Abstract

Neoadjuvant therapy is the cornerstone of modern rectal cancer treatment. Insights into the biology of tumor responses are essential for the successful implementation of organ-preserving strategies, as different treatments may lead to specific tumor responses. In this study, we aim to explore treatment-specific responses of the tumor microenvironment. Patients with locally advanced adenocarcinoma of the rectum who had received neo-adjuvant chemotherapy (CT), neo-adjuvant radiochemotherapy (RCT), neo-adjuvant radiotherapy with a long-interval (LRT) or short-interval (SRT) or no neoadjuvant therapy (NT) as control were included. Multiplex-immunofluorescence was performed to determine the presence of cytotoxic T-cells (T-cyt; CD3+CD8+), regulatory T-cells (T-reg; CD3+FOXP3+), T-helper cells (T-helper; CD3+CD8-FOXP3-), B cells (CD20+), dendritic cells (CD11c+) and tumor cells (panCK+). A total of 80 rectal cancer patients were included. Treatment groups were matched for gender, tumor location, response to therapy, and TNM stage. The pattern of response (shrinkage vs. fragmentation) was, however, different between treatment groups. Our analyses reveal that RCT-treated patients exhibited lower stromal T-helper, T-reg, and T-cyt cells compared to other treatment regimens. In conclusion, we demonstrated treatment-specific differences in the immune microenvironment landscape of rectal cancer patients. Understanding the underlying mechanisms of this landscape after a specific therapy will benefit future treatment decisions.

Published
2022

29. Prognostic importance of lymph node count and ratio in rectal cancer after neoadjuvant chemoradiotherapy: Results from a cross-sectional study

Author

Detering, Robin, Meyer, Vincent M., Borstlap, Wernard A. A., Beets-Tan, Regina G. H., Marijnen, Corrie A. M., Hompes, Roel, Tanis, Pieter J., van Westreenen, Henderik L., Aalbers, A. G. J., Acherman, Y., Algie, G. D., Alting von Geusau, B., Amelung, F., Aukema, T. S., Bakker, I. S., Bartels, S. A., Basha, S., Bastiaansen, A. J. N. M., Belgers, E., Bleeker, W., Blok, J., Bosker, R. J. I., Bosmans, J. W., Boute, M. C., Bouvy, N. D., Bouwman, H., Brandt-Kerkhof, A., Brinkman, D. J., Bruin, S., Bruns, E. R. J., Burbach, J. P. M., Burger, J. W. A., Buskens, C. J., Clermonts, S., Coene, P. P. L. O., Compaan, C., de Mik, S. M. L., van Duijvendijk, P., Gooszen, J. A. H., Hoogland, P., Lamme, B., Marres, C. C., Musters, G. D., van Rossem, C. C., Schreuder, A. M., Swank, H. A., Tuynman, J. B., van Beek, S. C., van Westreenen, H. L., Westerduin, E., Surgery, CCA - Cancer Treatment and Quality of Life, Amsterdam Gastroenterology Endocrinology Metabolism, Graduate School, AGEM - Endocrinology, metabolism and nutrition, CCA - Cancer Treatment and quality of life, Anatomy and neurosciences, General practice, VU University medical center, Obstetrics and gynaecology, and Amsterdam Reproduction & Development (AR&D)

Subjects
Oncology, medicine.medical_specialty, disease-free survival, Colorectal cancer, Cross-sectional study, survival, chemoradiotherapy, 03 medical and health sciences, 0302 clinical medicine, lymph nodes, Internal medicine, Medicine, Humans, Stage (cooking), rectal cancer, Lymph node, Neoplasm Staging, Netherlands, Retrospective Studies, business.industry, Rectal Neoplasms, General Medicine, medicine.disease, Prognosis, Total mesorectal excision, Neoadjuvant Therapy, Survival Rate, medicine.anatomical_structure, Cross-Sectional Studies, 030220 oncology & carcinogenesis, Lymphatic Metastasis, Cohort, Multivariate Analysis, 030211 gastroenterology & hepatology, Surgery, business, Chemoradiotherapy, Neoadjuvant chemoradiotherapy
Abstract

Background: The aim of this study was to determine the prognostic value of lymph node count (LNC) and lymph node ratio (LNR) in rectal cancer after neoadjuvant chemoradiotherapy (CRT). Methods: Patients who underwent neoadjuvant CRT and total mesorectal excision (TME) for Stage I–III rectal cancer were selected from a cross-sectional study including 71 Dutch centres. Primary outcome parameters were disease-free survival (DFS) and overall survival (OS). Prognostic significance of LNC and LNR (cut-off values 0.15, 0.20, 0.30) was tested for different (sub)groups. Results: From 2095 registered patients, 458 were included, of which 240 patients with LNC < 12 and 218 patients with LNC ≥ 12. LNC was not significantly associated with DFS (p = 0.35) and OS (p = 0.59). In univariable analysis, LNR was significantly associated with DFS and OS in the whole cohort and LNC subgroups, but not in multivariable analysis. Conclusions: LNC was not associated with long-term oncological outcome in rectal cancer patients treated with CRT, nor was LNR when corrected for N-stage. However, LNR might be used to identify subgroups of node-positive patients with a favourable outcome.

Published
2021

30. Interpreting the RAPIDO trial: factors to consider Reply

Author

Bahadoer, Renu R, Dijkstra, Esmée A, van Etten, Boudewijn, Marijnen, Corrie A M, Putter, Hein, Kranenbarg, Elma Meershoek-Klein, Nilsson, Per J, Glimelius, Bengt, van de Velde, Cornelis J H, Hospers, Geke A P, and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
Chemotherapy, Adjuvant, Rectal Neoplasms, Rectum, Humans, Chemoradiotherapy
Published
2021

32. Interpreting the RAPIDO trial: factors to consider – Authors' reply

Author

Bahadoer, Renu R, primary, Dijkstra, Esmée A, additional, van Etten, Boudewijn, additional, Marijnen, Corrie A M, additional, Putter, Hein, additional, Kranenbarg, Elma Meershoek-Klein, additional, Nilsson, Per J, additional, Glimelius, Bengt, additional, van de Velde, Cornelis J H, additional, and Hospers, Geke A P, additional

Published
2021
Full Text
View/download PDF

34. T 1ρ for Radiotherapy Treatment Response Monitoring in Rectal Cancer Patients: A Pilot Study.

Author

Kooreman, Ernst S., Tanaka, Max, ter Beek, Leon C., Peters, Femke P., Marijnen, Corrie A. M., van der Heide, Uulke A., and van Houdt, Petra J.

Subjects
RECTAL cancer, CANCER patients, PILOT projects, LINEAR accelerators, RADIOTHERAPY
Abstract

Quantitative MRI has the potential to produce imaging biomarkers for the prediction of early response to radiotherapy treatment. In this pilot study, a potential imaging biomarker, the T1ρ relaxation time, is assessed for this purpose. A T1ρ sequence was implemented on a 1.5 T MR-linac system, a system that combines an MRI with a linear accelerator for radiation treatment. An agar phantom with concentrations of 1–4% w/w was constructed for technical validation of the sequence. Phantom images were assessed in terms of short-term repeatability and signal-to-noise ratio. Twelve rectal cancer patients, who were treated with 5 × 5 Gy, were imaged on each treatment fraction. Individual changes in the T1ρ values of the gross tumor volume (GTV) showed an increase for most patients, although a paired t-test comparing values in the GTV from the first to the last treatment fraction showed no statistically significant difference. The phantom measurements showed excellent short-term repeatability (0.5–1.5 ms), and phantom T1ρ values corresponded to the literature values. T1ρ imaging was implemented successfully on the MR-linac, with a repeatability comparable to diagnostic systems, although clinical benefit in terms of treatment response monitoring remains to be demonstrated. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

35. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

Author

Bahadoer, Renu R, primary, Dijkstra, Esmée A, additional, van Etten, Boudewijn, additional, Marijnen, Corrie A M, additional, Putter, Hein, additional, Kranenbarg, Elma Meershoek-Klein, additional, Roodvoets, Annet G H, additional, Nagtegaal, Iris D, additional, Beets-Tan, Regina G H, additional, Blomqvist, Lennart K, additional, Fokstuen, Tone, additional, ten Tije, Albert J, additional, Capdevila, Jaume, additional, Hendriks, Mathijs P, additional, Edhemovic, Ibrahim, additional, Cervantes, Andrés, additional, Nilsson, Per J, additional, Glimelius, Bengt, additional, van de Velde, Cornelis J H, additional, Hospers, Geke A P, additional, Østergaard, L., additional, Svendsen Jensen, F., additional, Pfeiffer, P., additional, Jensen, K.E.J., additional, Hendriks, M.P., additional, Schreurs, W.H., additional, Knol, H.P., additional, van der Vliet, J.J., additional, Tuynman, J.B., additional, Bruynzeel, A.M.E., additional, Kerver, E.D., additional, Festen, S., additional, van Leerdam, M.E., additional, Beets, G.L., additional, Dewit, L.G.H., additional, Punt, C.J.A., additional, Tanis, P.J., additional, Geijsen, E.D., additional, Nieboer, P., additional, Bleeker, W.A., additional, Ten Tije, A.J., additional, Crolla, R.M.P.H., additional, van de Luijtgaarden, A.C.M., additional, Dekker, J.W.T., additional, Immink, J.M., additional, Jeurissen, F.J.F., additional, Marinelli, A.W.K.S., additional, Ceha, H.M., additional, Stam, T.C., additional, Quarles an Ufford, P., additional, Steup, W.H., additional, Imholz, A.L.T., additional, Bosker, R.J.I., additional, Bekker, J.H.M., additional, Creemers, G.J., additional, Nieuwenhuijzen, G.A.P., additional, van den Berg, H., additional, van der Deure, W.M., additional, Schmitz, R.F., additional, van Rooijen, J.M., additional, Olieman, A.F.T., additional, van den Bergh, A.C.M., additional, de Groot, D.J.A., additional, Havenga, K., additional, Beukema, J.C., additional, de Boer, J., additional, Veldman, P.H.J.M., additional, Siemerink, E.J.M., additional, Vanstiphout, J.W.P., additional, de Valk, B., additional, Eijsbouts, Q.A.J., additional, Polée, M.B., additional, Hoff, C., additional, Slot, A., additional, Kapiteijn, H.W., additional, Peeters, K.C.M.J., additional, Peters, F.P., additional, Nijenhuis, P.A., additional, Radema, S.A., additional, de Wilt, H., additional, Braam, P., additional, Veldhuis, G.J., additional, Hess, D., additional, Rozema, T., additional, Reerink, O., additional, Ten Bokkel Huinink, D., additional, Pronk, A., additional, Vos, J., additional, Tascilar, M., additional, Patijn, G.A., additional, Kersten, C., additional, Mjåland, O., additional, Grønlie Guren, M., additional, Nesbakken, A.N., additional, Benedik, J., additional, Edhemovic, I., additional, Velenik, V., additional, Capdevila, J., additional, Espin, E., additional, Salazar, R., additional, Biondo, S., additional, Pachón, V., additional, die Trill, J., additional, Aparicio, J., additional, Garcia Granero, E., additional, Safont, M.J., additional, Bernal, J.C., additional, Cervantes, A., additional, Espí Macías, A., additional, Malmberg, L., additional, Svaninger, G., additional, Hörberg, H., additional, Dafnis, G., additional, Berglund, A., additional, Österlund, L., additional, Kovacs, K., additional, Hol, J., additional, Ottosson, S., additional, Carlsson, G., additional, Bratthäll, C., additional, Assarsson, J., additional, Lödén, B.L., additional, Hede, P., additional, Verbiené, I., additional, Hallböök, O., additional, Johnsson, A., additional, Lydrup, M.L., additional, Villmann, K., additional, Matthiessen, P., additional, Svensson, J.H., additional, Haux, J., additional, Skullman, S., additional, Fokstuen, T., additional, Holm, T., additional, Flygare, P., additional, Walldén, M., additional, Lindh, B., additional, Lundberg, O., additional, Radu, C., additional, Påhlman, L., additional, Piwowar, A., additional, Smedh, K., additional, Palenius, U., additional, Jangmalm, S., additional, Parinkh, P., additional, Kim, H., additional, and Silviera, M.L., additional

Published
2021
Full Text
View/download PDF

38. End-of-Life Trajectories of Patients With Hematological Malignancies and Patients With Advanced Solid Tumors Visiting the Emergency Department: The Need for a Proactive Integrated Care Approach

Author

Verhoef, Mary-Joanne, primary, de Nijs, Ellen J. M., additional, Ootjers, Claudia S., additional, Fiocco, Marta, additional, Fogteloo, Anne J., additional, Heringhaus, Christian, additional, Marijnen, Corrie A. M., additional, Horeweg, Nanda, additional, and der Linden, Yvette M. van, additional

Published
2019
Full Text
View/download PDF

39. Supplemental Material, Appendix_1 - End-of-Life Trajectories of Patients With Hematological Malignancies and Patients With Advanced Solid Tumors Visiting the Emergency Department: The Need for a Proactive Integrated Care Approach

Author

Mary-Joanne Verhoef, Nijs, Ellen J. M. De, Ootjers, Claudia S., Fiocco, Marta, Fogteloo, Anne J., Heringhaus, Christian, Marijnen, Corrie A. M., Horeweg, Nanda, and Linden, Yvette M. Van Der

Subjects
111099 Nursing not elsewhere classified, 111702 Aged Health Care, FOS: Health sciences, humanities
Abstract

Supplemental Material, Appendix_1 for End-of-Life Trajectories of Patients With Hematological Malignancies and Patients With Advanced Solid Tumors Visiting the Emergency Department: The Need for a Proactive Integrated Care Approach by Mary-Joanne Verhoef, Ellen J. M. de Nijs, Claudia S. Ootjers, Marta Fiocco, Anne J. Fogteloo, Christian Heringhaus, Corrie A. M. Marijnen, Nanda Horeweg and Yvette M. van der Linden in American Journal of Hospice and Palliative Medicine®

Published
2019
Full Text
View/download PDF

42. Patient explicit consideration of tradeoffs in decision making about rectal cancer treatment: benefits for decision process and quality of life

Author

Pieterse, Arwen H., primary, Kunneman, Marleen, additional, van den Hout, Wilbert B., additional, Baas-Thijssen, Monique, additional, Geijsen, Elisabeth D., additional, Ceha, Heleen M., additional, Muller, Karin M., additional, van der Linden, Yvette M., additional, Marijnen, Corrie A. M., additional, and Stiggelbout, Anne M., additional

Published
2019
Full Text
View/download PDF

43. End-of-Life Trajectories of Patients With Hematological Malignancies and Patients With Advanced Solid Tumors Visiting the Emergency Department: The Need for a Proactive Integrated Care Approach.

Author

Verhoef, Mary-Joanne, de Nijs, Ellen J. M., Ootjers, Claudia S., Fiocco, Marta, Fogteloo, Anne J., Heringhaus, Christian, Marijnen, Corrie A. M., Horeweg, Nanda, and der Linden, Yvette M. van

Abstract

Purpose: Patients with hematological malignancies (HM) have more unpredictable disease trajectories compared to patients with advanced solid tumors (STs) and miss opportunities for a palliative care approach. They often undergo intensive disease-directed treatments until the end of life with frequent emergency department (ED) visits and in-hospital deaths. Insight into end-of-life trajectories and quality of end-of-life care can support arranging appropriate care according to patients' wishes. Method: Mortality follow-back study to compare of end-of-life trajectories of HM and ST patients who died <3 months after their ED visit. Five indicators based on Earle et al. for quality of end-of-life care were assessed: intensive anticancer treatment <3 months, ED visits <6 months, in-hospital death, death in the intensive care unit (ICU), and in-hospice death. Results: We included 78 HM patients and 420 ST patients, with a median age of 63 years; 35% had Eastern Cooperative Oncology Group performance status 3-4. At the ED, common symptoms were dyspnea (22%), pain (18%), and fever (11%). After ED visit, 91% of HM patients versus 76% of ST patients were hospitalized (P =.001). Median survival was 17 days (95% confidence interval [CI]: 15-19): 15 days in HM patients (95% CI: 10-20) versus 18 days in ST patients (95% CI: 15-21), P =.028. Compared to ST patients, HM patients more often died in hospital (68% vs 30%, P <.0001) and in the ICU or ED (30% vs 3%, P <.0001). Conclusion: Because end-of-life care is more aggressive in HM patients compared to ST patients, a proactive integrated care approach with early start of palliative care alongside curative care is warranted. Timely discussions with patients and family about advance care planning and end-of-life choices can avoid inappropriate care at the end of life. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

44. Tumoren van dunne en dikke darm

Author

Tanis, Pieter J., Beets-Tan, Regina G. H., Marijnen, Corrie A. M., Nagtegaal, Iris D., Punt, Cornelis J. A., van de Velde, C .J. H., van der Graaf, W. T. A., van Krieken, J. H. J. M., Marijnen, C. A. M., Amsterdam Gastroenterology Endocrinology Metabolism, CCA - Treatment and quality of life, Surgery, Cancer Center Amsterdam, and Oncology

Subjects
business.industry, Medicine, business
Published
2017

45. Can we Save the rectum by watchful waiting or TransAnal microsurgery following (chemo) Radiotherapy versus Total mesorectal excision for early REctal Cancer (STAR-TREC study)?: protocol for a multicentre, randomised feasibility study

Author

Rombouts, Anouk J M, primary, Al-Najami, Issam, additional, Abbott, Natalie L, additional, Appelt, Ane, additional, Baatrup, Gunnar, additional, Bach, Simon, additional, Bhangu, Aneel, additional, Garm Spindler, Karen-Lise, additional, Gray, Richard, additional, Handley, Kelly, additional, Kaur, Manjinder, additional, Kerkhof, Ellen, additional, Kronborg, Camilla Jensenius, additional, Magill, Laura, additional, Marijnen, Corrie A M, additional, Nagtegaal, Iris D, additional, Nyvang, Lars, additional, Peters, Femke P, additional, Pfeiffer, Per, additional, Punt, Cornelis, additional, Quirke, Philip, additional, Sebag-Montefiore, David, additional, Teo, Mark, additional, West, Nick, additional, and de Wilt, Johannes H W, additional

Published
2017
Full Text
View/download PDF

47. Long-term Oncological and Functional Outcomes of Chemoradiotherapy Followed by Organ-Sparing Transanal Endoscopic Microsurgery for Distal Rectal Cancer: The CARTS Study.

Author

Stijns, Rutger C. H., de Graaf, Eelco J. R., Punt, Cornelis J. A., Nagtegaal, Iris D., Nuyttens, Joost J. M. E., van Meerten, Esther, Tanis, Pieter J., de Hingh, Ignace H. J. T., van der Schelling, George P., Acherman, Yair, Leijtens, Jeroen W. A., Bremers, Andreas J. A., Beets, Geerard L., Hoff, Christiaan, Verhoef, Cornelis, Marijnen, Corrie A. M., de Wilt, Johannes H. W., and CARTS Study Group

Published
2019
Full Text
View/download PDF

48. Clinicopathological characteristics predict lymph node metastases in ypT0-2 rectal cancer after chemoradiotherapy

Author

Bosch, Steven L, primary, Vermeer, Thomas A, additional, West, Nicholas P, additional, Swellengrebel, Hendrik A M, additional, Marijnen, Corrie A M, additional, Cats, Annemieke, additional, Verhoef, Cornelis, additional, van Lijnschoten, Ineke, additional, de Wilt, Johannes H W, additional, Rutten, Harm J, additional, and Nagtegaal, Iris D, additional

Published
2016
Full Text
View/download PDF

50. Screening for psychological distress before radiotherapy for painful bone metastases may be useful to identify patients with high levels of distress.

Author

Westhoff, Paulien G., de Graeff, Alexander, Monninkhof, Evelyn M., Berveling, Maaike J., van Vulpen, Marco, Leer, Jan Willem H., Marijnen, Corrie A. M., Reyners, Anna K. L., and van der Linden, Yvette M.

Subjects
RADIOTHERAPY, PSYCHOLOGICAL stress, CANCER pain, AGE distribution, BONE metastasis, CANCER patient psychology, LONGITUDINAL method, QUALITY of life, QUESTIONNAIRES, STATISTICAL sampling, SEX distribution, MULTIPLE regression analysis, TREATMENT effectiveness, PRE-tests & post-tests, DESCRIPTIVE statistics, PSYCHOLOGY
Abstract

Background:Psychological distress (PD) has a major impact on quality of life. We studied the incidence of PD before and after radiotherapy for painful bone metastases. Furthermore, we aimed to identify factors predictive for PD. Methods:Between 1996 and 1998, the Dutch Bone Metastasis Study included 1157 patients with painful bone metastases. Patients were randomized between two fractionation schedules. The study showed a pain response of 74% in both groups. Patients filled out weekly questionnaires for 13 weeks, then monthly for two years. The questionnaires included a subscale for PD on the Rotterdam Symptom Checklist. We used generalized estimating equations and multivariable logistic regression analyses. Results:At baseline, 290 patients (27%) had a high level of PD. For the entire group, the level of PD remained constant over time. The majority of patients with a low level of PD at baseline remained at a low level during follow-up. In patients with a high level of PD at baseline, the mean level of PD decreased after treatment and stabilized around the cutoff level. Female patients, higher age, worse performance, lower pain score and worse self-reported QoL were associated with an increased chance of PD, although the model showed moderate discriminative power. Conclusions:A substantial proportion of patients had a high level of PD before and after radiotherapy for painful bone metastases. Most patients who reported high levels of PD when referred for palliative radiotherapy remained at high levels thereafter. Therefore, screening of PD prior to treatment seems appropriate, in order to select patients requiring intervention. [ABSTRACT FROM PUBLISHER]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results